ETON · Categories · Form 4

ETON - SEC Form 4 insider transactions

Eton Pharmaceuticals Inc. (ETON) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ETON

• 5d
  President & CEO Brynjelsen Sean sold $3,825,717 worth of shares (120,000 units at $31.88), decreasing direct ownership by 13% to 833,694 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 7d
  Chief Business Officer Krempa David exercised 87,794 shares at a strike of $2.32 and sold $3,229,923 worth of shares (100,000 units at $32.30), decreasing direct ownership by 33% to 25,249 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 42d
  SEC Form 4 filed by Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 118d
  Director Riedel Norbert G exercised 30,000 in-the-money shares at a strike of $4.42, increasing direct ownership by 600% to 35,000 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  SEC Form 4 filed by Director Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  SEC Form 4 filed by Director Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  SEC Form 4 filed by Director Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  SEC Form 4 filed by Director Maier Paul V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  SEC Form 4 filed by Chief Commercial Officer Erdogan-Trinkaus Ipek

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  President & CEO Brynjelsen Sean covered exercise/tax liability with 5,015 shares, decreasing direct ownership by 0.17% to 2,889,266 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  Chief Business Officer Krempa David covered exercise/tax liability with 1,942 shares, decreasing direct ownership by 0.31% to 630,238 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 140d
  Chief Financial Officer Gruber James R. covered exercise/tax liability with 2,293 shares, decreasing direct ownership by 1% to 213,420 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 173d
  Chief Commercial Officer Erdogan-Trinkaus Ipek covered exercise/tax liability with 85 shares, decreasing direct ownership by 3% to 2,403 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 173d
  Chief Business Officer Krempa David covered exercise/tax liability with 6,264 shares, decreasing direct ownership by 0.98% to 632,180 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 173d
  Chief Financial Officer Gruber James R. covered exercise/tax liability with 4,542 shares, decreasing direct ownership by 2% to 215,713 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 173d
  President & CEO Brynjelsen Sean covered exercise/tax liability with 6,732 shares, decreasing direct ownership by 0.23% to 2,894,281 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 287d
  Chief Financial Officer Gruber James R. sold $673,714 worth of shares (41,713 units at $16.15), decreasing direct ownership by 16% to 204,753 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 352d
  Chief Business Officer Krempa David sold $504,318 worth of shares (34,000 units at $14.83), decreasing direct ownership by 5% to 612,646 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 363d
  President & CEO Brynjelsen Sean sold $3,592,611 worth of shares (210,000 units at $17.11), decreasing direct ownership by 7% to 2,873,513 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by Director Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  Director Riedel Norbert G exercised 102,400 shares at a strike of $3.65, increasing direct ownership by 171% to 162,145 units (SEC Form 4)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by Director Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by Director Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by Director Maier Paul V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by President & CEO Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by Chief Business Officer Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 513d
  SEC Form 4 filed by Chief Financial Officer Gruber James R.

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 607d
  SEC Form 4 filed by Chief Business Officer Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Gruber James R.

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Adams Jennifer Mckie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Casamento Charles J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Krempa David

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Maier Paul V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 839d
  SEC Form 4 filed by Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1349d
  SEC Form 4: Brynjelsen Sean bought $21,042 worth of shares (10,000 units at $2.10), increasing direct ownership by 0.97% to 1,040,000 units

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1416d
  SEC Form 4 filed by Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1416d
  SEC Form 4 filed by Gruber James R.

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1556d
  SEC Form 4 filed by Troutman William Wilson

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1556d
  SEC Form 4 filed by Riedel Norbert G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1556d
  SEC Form 4 filed by Brynjelsen Sean

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1657d
  SEC Form 4: Opaleye Management Inc. sold $116,712 worth of shares (25,000 units at $4.67)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1659d
  SEC Form 4: Opaleye Management Inc. sold $74,877 worth of shares (15,438 units at $4.85)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1667d
  SEC Form 4: Opaleye Management Inc. sold $1,377,986 worth of shares (220,362 units at $6.25)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1671d
  SEC Form 4: Opaleye Management Inc. sold $1,312,501 worth of shares (202,200 units at $6.49)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1694d
  SEC Form 4: Opaleye Management Inc. sold $830,670 worth of shares (165,100 units at $5.03)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1748d
  SEC Form 4: Troutman William Wilson bought $22,150 worth of Common Stock (5,000 units at $4.43), increasing direct ownership by 28% to 23,027 units

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1748d
  SEC Form 4: BRYNJELSEN SEAN bought $43,200 worth of Common Stock (10,000 units at $4.32), increasing direct ownership by 0.98% to 1,030,000 units

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1761d
  SEC Form 4: Opaleye Management Inc. sold $3,523,187 worth of Common Stock (604,500 units at $5.83)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1808d
  SEC Form 4: Opaleye Management Inc. sold $847,350 worth of Common Stock (105,000 units at $8.07) (Amendment)

  4/A - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1812d
  SEC Form 4: Opaleye Management Inc. sold $847,350 worth of Common Stock (105,000 units at $8.07)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1826d
  SEC Form 4: BRYNJELSEN SEAN bought $29,800 worth of Common Stock (5,000 units at $5.96), increasing direct ownership by 0.49% to 1,030,000 units

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1833d
  SEC Form 4: Opaleye Management Inc. sold $2,064,511 worth of Common Stock (242,300 units at $8.52)

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1855d
  SEC Form 4 filed by BRYNJELSEN SEAN

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1855d
  SEC Form 4 filed by RIEDEL NORBERT G

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1855d
  SEC Form 4 filed by CASAMENTO CHARLES J

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1855d
  SEC Form 4 filed by MAIER PAUL V

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1855d
  SEC Form 4 filed by Adams Jennifer McKie

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1855d
  SEC Form 4 filed by Troutman William Wilson

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
• 1878d
  SEC Form 4: Inc. Health, Harrow sold $10,626,000 worth of Common Stock (1,518,000 units at $7.00), decreasing direct ownership by 43% to 1,982,000 units

  4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

Other ETON categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends